Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SGLT2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT06128096
What this trial is testing

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)

Who this might be right for
Coronary Artery Disease
Clinical Research Centre, Malaysia 360
Testing effectiveness (Phase 2)UnknownNCT04304560
What this trial is testing

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Who this might be right for
Heart Failure With Reduced Ejection Fraction (HFrEF)Diabete Type 2Cardiomyopathies
Damanhour University 60
Post-approval studies (Phase 4)Temporarily pausedNCT05435235
What this trial is testing

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Who this might be right for
Acute Kidney InjuryPercutaneous Coronary Intervention
Albert Einstein Healthcare Network 250
Not applicableStudy completedNCT05640180
What this trial is testing

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Who this might be right for
Chronic Kidney DiseaseType 2 Diabetes
Bayer 17,847
Post-approval studies (Phase 4)Study completedNCT03007329
What this trial is testing

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Who this might be right for
Steatosis, LiverType2 Diabetes
Medical University of Vienna 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06072326
What this trial is testing

DApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Who this might be right for
Type 1 Diabetes Mellitus With Diabetic Nephropathy
University Medical Center Groningen 36
Not applicableUnknownNCT05477017
What this trial is testing

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Who this might be right for
Type2Diabetes
University of Milan 800
Testing effectiveness (Phase 2)Study completedNCT07610174
What this trial is testing

Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

Who this might be right for
Heart FailureHeart Valve Prosthesis
Kafrelsheikh University 160
Large-scale testing (Phase 3)Study completedNCT07591077
What this trial is testing

SGLT2 Adjunct in T1D

Who this might be right for
Type 1 DiabetesNephropathy, Diabetic
Ain Shams University 86
Not applicableStudy completedNCT02297620
What this trial is testing

The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Who this might be right for
Type 2 Diabetes
Astellas Pharma Inc 8,687
Not applicableStudy completedNCT02636192
What this trial is testing

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Who this might be right for
Diabetes Mellitus, Type 2
Janssen Research & Development, LLC 200,000
Early research (Phase 1)Study completedNCT00836225
What this trial is testing

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Who this might be right for
Type 2 Diabetes Mellitus
Ionis Pharmaceuticals, Inc. 103
Testing effectiveness (Phase 2)Study completedNCT03093103
What this trial is testing

Empagliflozin and Renal Oxygenation in Healthy Volunteers

Who this might be right for
Nephropathy
Centre Hospitalier Universitaire Vaudois 45
Large-scale testing (Phase 3)Looking for participantsNCT07214818
What this trial is testing

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

Who this might be right for
Nephrotic Syndrome
Mansoura University 75
Post-approval studies (Phase 4)UnknownNCT04796428
What this trial is testing

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Who this might be right for
Diabetes Mellitus, Type 2
Center for Outcomes Research and Clinical Epidemiology, Italy 1,167
Testing effectiveness (Phase 2)Study completedNCT01248364
What this trial is testing

Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 91
Not applicableUnknownNCT06097585
What this trial is testing

Gliflozins on HF in Regurgitant Rheumatic Heart

Who this might be right for
Rheumatic Heart DiseaseHeart Failure
Assiut University 150
Post-approval studies (Phase 4)Study completedNCT02175784
What this trial is testing

Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Who this might be right for
Type 2 Diabetes Mellitus
Astellas Pharma Inc 262
Large-scale testing (Phase 3)Study completedNCT05283057
What this trial is testing

Empagliflozin in Patients With Glomerulonephritis

Who this might be right for
GlomerulonephritisProteinuria
Kasr El Aini Hospital 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT07537088
What this trial is testing

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Who this might be right for
T2DM (Type 2 Diabetes Mellitus)CKD - Chronic Kidney Disease
First Affiliated Hospital of Wannan Medical College 468
Next Page